Skip to main content
Premium Trial:

Request an Annual Quote

Inforsense to Distribute Pharsight's Software in China

NEW YORK (GenomeWeb News) – Pharsight has signed up Inforsense to distribute its products in China through its subsidiary in Shanghai.
Under the agreement, Inforsense will market Pharsight’s software, which is used in pharmacokinetic and pharmacodynamic analysis, reporting, archiving, and data visualization. Inforsense will distribute the software in the Chinese pharmaceutical and biotech research and development market, and conduct sales and marketing, end-user training, and maintenance and support services.
The companies also have agreed to partner to develop translational research solutions for drug developers, and they may collaborate to use biomarkers in clinical PK/PD modeling.
"Bringing together our capabilities in genotypic and other molecular analysis with Pharsight's PK/PD tools and expertise is a major step towards making the goal of translational research a reality,” Inforsense Chief Scientific Officer Jonathan Sheldon said in a statement.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.